Preussmann R, Schmähl D, Eisenbrand G
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Nov 18;90(2):161-6. doi: 10.1007/BF00285322.
Results from a dose-response study in rats are reported, in which daily oral doses of 10, 3, 1, and 0.3 mg/kg bodyweight/day respectively were administered. The three highest dose levels resulted in incidences of liver cancer of 46, 84, and 32% respectively. In the lowest dose group (0.3 mg/kg/day) no statistically significant increase in tumor rate compared to untreated controls was found.
报告了一项大鼠剂量反应研究的结果,其中分别给予每日口服剂量为10、3、1和0.3毫克/千克体重/天。三个最高剂量水平导致肝癌发生率分别为46%、84%和32%。在最低剂量组(0.3毫克/千克/天)中,与未处理的对照组相比,未发现肿瘤发生率有统计学上的显著增加。